In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in CLL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies and topics include:

ASCEND: acalabrutinib vs idelalisib plus rituximab or BR
ACE-CL-001: acalabrutinib long-term efficacy
CLL14: Venetoclax plus obinutuzumab
CLARITY: Ibrutinib plus venetoclax
Measurable residual disease (MRD)
Complex karyotypes
Zanubrutinib plus obinutuzumab and venetoclax

Presenters:

Jennifer R. Brown, MD, PhD
Associate Professor of Medicine
Department of Hematologic Malignancies
Dana-Farber Cancer Institute
Harvard Medical School
Director, CLL Center
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

John Allan, MD
Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program: https://bit.ly/3aSfekM

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: CLL